Cite
Limited long‐term treatment persistence of first anti‐TNF therapy in 538 patients with inflammatory bowel diseases: a 20‐year real‐world study.
MLA
Blesl, Andreas, et al. “Limited Long‐term Treatment Persistence of First Anti‐TNF Therapy in 538 Patients with Inflammatory Bowel Diseases: A 20‐year Real‐world Study.” Alimentary Pharmacology & Therapeutics, vol. 54, no. 5, Sept. 2021, pp. 667–77. EBSCOhost, https://doi.org/10.1111/apt.16478.
APA
Blesl, A., Binder, L., Högenauer, C., Wenzl, H., Borenich, A., Pregartner, G., Berghold, A., Mestel, S., Kump, P., Baumann, D. F., & Petritsch, W. (2021). Limited long‐term treatment persistence of first anti‐TNF therapy in 538 patients with inflammatory bowel diseases: a 20‐year real‐world study. Alimentary Pharmacology & Therapeutics, 54(5), 667–677. https://doi.org/10.1111/apt.16478
Chicago
Blesl, Andreas, Lukas Binder, Christoph Högenauer, Heimo Wenzl, Andrea Borenich, Gudrun Pregartner, Andrea Berghold, et al. 2021. “Limited Long‐term Treatment Persistence of First Anti‐TNF Therapy in 538 Patients with Inflammatory Bowel Diseases: A 20‐year Real‐world Study.” Alimentary Pharmacology & Therapeutics 54 (5): 667–77. doi:10.1111/apt.16478.